Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients-Reference-Cited by-同舟云学术

Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients

Published:2024-03-18 Issue:7 Volume:80 Page:951-963
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Tanashat Mohammad,Manasrah Almothana,Abouzid Mohamed

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00228-024-03660-2.pdf

Reference39 articles.

1. Metra M, Carubelli V, Ravera A, Stewart Coats AJ (2017) Heart failure 2016: Still more questions than answers. Int J Cardiol 227:766–777. https://doi.org/10.1016/j.ijcard.2016.10.060

2. Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K, Shah SJ, Van Spall HGC (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart Br Card Soc 108:1342–1350. https://doi.org/10.1136/heartjnl-2021-319605

3. Nayor M, Houstis NE, Namasivayam M, Rouvina J, Hardin C, Shah RV, Ho JE, Malhotra R, Lewis GD (2020) Impaired exercise tolerance in heart failure with preserved ejection fraction: Quantification of multiorgan system reserve capacity. JACC Heart Fail 8:605–617. https://doi.org/10.1016/j.jchf.2020.03.008

4. Xie Y, Wei Y, Li D, Pu J, Ding H, Zhang X (2023) Mechanisms of SGLT2 inhibitors in heart failure and their clinical value. J Cardiovasc Pharmacol 81:4. https://doi.org/10.1097/FJC.0000000000001380

5. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM (2017) DEPICT-1 Investigators efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3. Randomised Controlled Trial Lancet Diabetes Endocrinol 5:864–876. https://doi.org/10.1016/S2213-8587(17)30308-X

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author’s reply to the letter to the editor: “Effects of dapagliflozin and empagliflozin on 6‑min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta‑analysis of randomized controlled trials involving 2624 patients”;European Journal of Clinical Pharmacology;2024-07-23

2. Letter to the editor: "Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients";European Journal of Clinical Pharmacology;2024-07-21

3. Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density;Current Opinion in Lipidology;2024-07-18